← All trials
NCT00594269
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2008
- Primary completion
- Dec 1, 2010
- Completion date
- Dec 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 149
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Sykehuset Innlandet HFLead sponsor
- Sykehuset Innlandet HFOverall official - principal investigator
- The Norwegian Centre for Dementia ResearchStudy chair
- University of BergenCollaborator
- Diakonhjemmet HospitalCollaborator
- Telemark Hospital TrustCollaborator
- Songdalstunet Nursing HomeCollaborator
- Sykehuset Innlandet HFCollaborator
- Helse Møre og Romsdal HFCollaborator
- Sykehuset BuskerudCollaborator
- University of OsloCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.